Pulmonary%20arterial%20hypertension Treatment

Treatment

Surgical Intervention

Balloon Atrial Septostomy (BAS)

Several experimental and clinical observations suggest that an atrial defect may be of benefit in the setting of pulmonary hypertension (PH) as it would allow right to left shunting which increases systemic output
- This would increase systemic arterial oxygen saturation
- It also decompresses the right atrium and ventricle therefore decreasing signs and symptoms of right heart failure

At present, indications for BAS are:
- Patients who are in World Health Organization functional class (WHO FC) IV with severe syncope and/or right heart failure despite all available medical treatments
- Palliative bridge to lung transplantation
- Sole treatment modality when other options are not available
- Considered in pulmonary arterial hypertension (PAH) associated with surgically corrected congenital hear disease (CHD), connective tissue disease, distal chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis
- May be considered before severe hemodynamic compromise and end-organ dysfunction occur

Should be performed only at institutions with significant procedural and clinical experience
Avoided in patients with a baseline mean right atrial pressure (RAP) >20 mmHg and O₂ saturation at rest of <85% on room air

Transplantation

There is no agreement on the optimal type of transplantation for patients with PAH, whether single lung, double lung or combined heart and lung
Indicated in PAH patients when they have an unacceptable response to PAH therapies seen in FC III or IV
Due to lack of effective medical therapeutic regimen, patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis should be candidates for transplantation at diagnosis
Overall 5-year survival rates in PAH patients following transplant have been recorded at 45-50% and are continually increasing
- Recent records showed 52-75% at 5 years and 45-66% at 10 years

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Antigen rapid test vs RT-PCR for COVID-19: What you need to know

Pearl Toh, 29 Jul 2021

While RT-PCR is the current gold standard to confirm a SARS-CoV-2 infection, antigen rapid test (ART) for COVID-19 allows for quick detection of SARS-CoV-2 and thus fast triaging of infected patients requiring isolation at the population level, according to studies presented at ECCMID 2021.

Tackling multidrug-resistant gram-negative bacterial infections in critically ill patients: Challenging the standard approach

Dr. Asok Kurup, Dr. Kenneth Chan, 07 Dec 2020

The rising incidence of infections caused by multidrug-resistant (MDR) gram-negative bacteria has become a serious health threat and a major challenge for intensivists. Against a backdrop of high patient mortality and risk factors for infection in intensive care units (ICU), early adequate therapy is of paramount importance. At a recent Pfizer-sponsored symposium, Dr Asok Kurup, Infectious Disease Physician, Singapore presented the implications of MDR gram-negative infections in critically ill patients in Asia, while Dr Kenneth Chan, Respiratory Physician and Intensivist, Singapore highlighted the role of ceftazidime-avibactam (Zavicefta) and shared published real-world data on ceftazidime-avibactam.